Icatibant Fresenius (Icatibant Acetate)

Icatibant acetate is a competitive antagonist of the bradykinin B2 receptor on vascular endothelial cells. By occupying this receptor, it prevents bradykinin from triggering vasodilation and increased vascular permeability, which are responsible for the localized edema seen in hereditary angioedema. The effect is dose‑dependent and reversible as the drug is cleared.

The dosing regimen for Icatibant Fresenius is determined by the prescribing clinician based on the patient’s weight, severity of the attack, and clinical guidelines. Typically, a single subcutaneous injection is administered at the onset of an HAE attack, with additional doses allowed if symptoms persist, as directed by the healthcare professional.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician, who can assess individual risk factors.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other approved therapies such as C1‑esterase inhibitor concentrates replace the deficient protein, and newer monoclonal antibodies target upstream pathways. Icatibant offers rapid subcutaneous administration and fast symptom relief, but selection depends on patient preference, attack severity, and physician assessment of efficacy, safety, and convenience.

Icatibant Fresenius must be stored refrigerated between 2 °C and 8 °C. The product should be kept in its original packaging, protected from light, and must not be frozen or shaken. If temporary temperature excursions occur, the vial should be inspected for discoloration or particulate matter before use, and any deviation from recommended conditions should be reported to the supplier.

Icatibant is given by a single subcutaneous injection, usually into the abdomen or thigh. The injection site should be cleaned with an alcohol swab, and the pre‑filled syringe or vial is used according to the manufacturer’s instructions. Patients or caregivers can be trained to self‑administer, allowing prompt treatment at the first sign of an HAE attack.

The most serious adverse events include severe hypersensitivity reactions such as anaphylaxis, airway angioedema that may compromise breathing, and rare cases of profound hypotension. Prompt recognition of these symptoms and immediate medical intervention are essential. Patients should be educated to seek emergency care if they experience difficulty breathing, swelling of the throat, or a sudden drop in blood pressure after injection.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant acetate or any of its excipients. Caution is also advised for patients with a history of severe angioedema unrelated to hereditary forms, or those who have experienced anaphylactic reactions to similar biologic agents. In such cases, alternative therapies should be considered under medical supervision.